Centralized Pan-Asian Survey on the Under Treatment of Hypercholesterolemia (CEPHEUS)

AstraZeneca

Status: Completed

Conditions: Hypercholesterolemia

Study type: Observational

Funder types: Industry

Identifiers

NCT00687492

NIS-CAP-DUM-2008/1

Details and patient eligibility

About

The survey will try to establish the proportion of patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the third NCEP ATP guidelines, overall and by country.

Enrollment: 8,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 2 or more risk factors (according to NCEP ATP III guideline)
• Receiving lipid-lowering drug treatment for at least 3 months without dosage change for a minimum of 6 weeks.

Exclusion criteria

• Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
• Previous enrolment or randomisation of treatment in the present study.
• Participation in a clinical study during the last 90 days.